Tom Shea, Meitheal Pharmaceuticals CEO
June 27, 2023 10:48 AM EDT
Deals
R&D

Xen­tria and Meitheal ink li­cens­ing deal for rare lung dis­ease treat­ment in North Amer­i­ca

Tyler Patchen

News Reporter

Xen­tria will li­cense its ex­per­i­men­tal pul­monary sar­coido­sis drug to Meitheal Phar­ma­ceu­ti­cals in a deal worth up to $680 mil­lion.

Meitheal spun out Xen­tria in 2020 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Sanofi re­veals pos­i­tive da­ta for BTK in­hibitor from $3.7B Prin­cip­ia takeover

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times